KR20240124992A - 피리미딘 헤테로시클릭 화합물, 그의 제조 방법 및 의약에서의 그의 용도 - Google Patents

피리미딘 헤테로시클릭 화합물, 그의 제조 방법 및 의약에서의 그의 용도 Download PDF

Info

Publication number
KR20240124992A
KR20240124992A KR1020247023947A KR20247023947A KR20240124992A KR 20240124992 A KR20240124992 A KR 20240124992A KR 1020247023947 A KR1020247023947 A KR 1020247023947A KR 20247023947 A KR20247023947 A KR 20247023947A KR 20240124992 A KR20240124992 A KR 20240124992A
Authority
KR
South Korea
Prior art keywords
alkyl
alkylene
ring
membered
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247023947A
Other languages
English (en)
Korean (ko)
Inventor
훙푸 루
징징 펑
샤오 딩
진신 리우
잉타오 리우
펑 런
푸성 저우
타오 장
타오 량
지옹 랜
키앙 루
Original Assignee
인실리코 메디신 아이피 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인실리코 메디신 아이피 리미티드 filed Critical 인실리코 메디신 아이피 리미티드
Publication of KR20240124992A publication Critical patent/KR20240124992A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020247023947A 2021-12-22 2022-12-21 피리미딘 헤테로시클릭 화합물, 그의 제조 방법 및 의약에서의 그의 용도 Pending KR20240124992A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202111583828.0 2021-12-22
CN202111583828 2021-12-22
CN202210098381 2022-01-27
CN202210098381.6 2022-01-27
CN202210562007.7 2022-05-23
CN202210562007 2022-05-23
CN202211568373 2022-12-07
CN202211568373.X 2022-12-07
PCT/CN2022/140669 WO2023116761A1 (zh) 2021-12-22 2022-12-21 嘧啶杂环化合物，其制法与医药上的用途

Publications (1)

Publication Number Publication Date
KR20240124992A true KR20240124992A (ko) 2024-08-19

Family

ID=86901286

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247023947A Pending KR20240124992A (ko) 2021-12-22 2022-12-21 피리미딘 헤테로시클릭 화합물, 그의 제조 방법 및 의약에서의 그의 용도

Country Status (8)

Country Link
US (1) US20250145632A1 (enExample)
EP (1) EP4455132A4 (enExample)
JP (1) JP2025502602A (enExample)
KR (1) KR20240124992A (enExample)
CN (1) CN118647607A (enExample)
AR (1) AR128066A1 (enExample)
TW (1) TW202340211A (enExample)
WO (1) WO2023116761A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118556065A (zh) * 2022-01-28 2024-08-27 江苏奥赛康药业有限公司 含吲哚的大环类化合物及其应用
CN117964628A (zh) * 2022-10-24 2024-05-03 科辉智药生物科技(深圳)有限公司 作为cdk9抑制剂的大环类化合物及其应用
TW202500154A (zh) * 2023-06-19 2025-01-01 香港商英矽智能科技知識產權有限公司 大環類化合物、包含其的藥物組合物及其在醫藥上的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
MX358346B (es) * 2014-04-04 2018-08-15 Syros Pharmaceuticals Inc Inhibidores de la quinasa dependiente de ciclina 7 (cdk7).
SG11201900328WA (en) * 2016-07-13 2019-02-27 Jason Marineau Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA3088529A1 (en) * 2018-01-16 2019-07-25 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3873462A4 (en) 2018-11-01 2022-08-03 Syros Pharmaceuticals, Inc. CANCER TREATMENT METHODS IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLINE-DEPENDENT KINASE 7 (CDK7)
US20230115945A1 (en) * 2019-12-30 2023-04-13 Tyra Biosciences, Inc. Aminopyrimidine compounds
CN118556065A (zh) * 2022-01-28 2024-08-27 江苏奥赛康药业有限公司 含吲哚的大环类化合物及其应用

Also Published As

Publication number Publication date
CN118647607A (zh) 2024-09-13
EP4455132A1 (en) 2024-10-30
JP2025502602A (ja) 2025-01-28
TW202340211A (zh) 2023-10-16
EP4455132A4 (en) 2025-06-25
US20250145632A1 (en) 2025-05-08
AR128066A1 (es) 2024-03-20
WO2023116761A1 (zh) 2023-06-29

Similar Documents

Publication Publication Date Title
CN117645614B (zh) 取代的杂环并环类化合物，其制法与医药上的用途
CN113767106B (zh) 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途
CN115551867B (zh) 稠合三环类化合物、其药物组合物及用途
TWI841200B (zh) 雜環類化合物、藥物組成物及其應用
KR20230157463A (ko) 피리미딘-융합된 환형 화합물, 이의 제조 방법 및 이의 용도
EP4573089A2 (en) Kras inhibitors
RU2670762C2 (ru) Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
KR102665763B1 (ko) 알로스테릭 shp2 억제제로서의 이환 화합물
US11414429B2 (en) Compound or pharmaceutically acceptable salt thereof
JP2021176870A (ja) アロステリックｓｈｐ２阻害剤としての２，５−二置換３−メチルピラジンおよび２，５，６−三置換３−メチルピラジン
RU2723985C9 (ru) Соединение-ингибитор мультикиназ и его кристаллическая форма и применение
EP4455132A1 (en) Pyrimidine heterocyclic compound, preparation method therefor and use thereof in medicine
KR20220018483A (ko) 비스헤테로사이클릭 카보닐 치환된 디하이드로피라졸 화합물, 이의 제조방법 및 이의 약학적 용도
WO2021092525A1 (en) Wdr5 inhibitors and modulators
JP2024502301A (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
US20240034731A1 (en) Aza-quinazoline compounds and methods of use
TW202233598A (zh) PPARγ調節劑及使用方法
EP4223753A1 (en) Aroyl substituted tricyclic compound, preparation method therefor and use thereof
US20250235456A1 (en) Methods of use for aza-quinazoline compounds
TW202225163A (zh) 芳香雜環類化合物、藥物組合物及其應用
KR20240016977A (ko) 2,8-디아자스피로[4.5]데칸 화합물
HK40096984A (en) Aroyl substituted tricyclic compound, preparation method therefor and use thereof
HK1234395B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000